Company intelligence / Profile preview

EyeBio

Ownership: Private
Development stage: Phase 2

Overview

EyeBio has developed Restoret™ (EYE103), an investigational first-in-class tetravalent, tri-specific antibody acting as a Wnt pathway agonist for retinal diseases. Positive safety and tolerability data were reported from the open-label Phase 1b/2a AMARONE study for DME and NVAMD patients. The lead asset will enter pivotal trials for DME in late 2024.

Therapeutic areas: Ophthalmology
Modalities: Multispecific antibodies (tetravalent, tri-specific antibody)Biologics
Industry: Biotech

Drug pipeline

2 assets

EB-203

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on EyeBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EyeBio.

Explore the full profile